Last updated on March 2019

Post Marketing Surveillance on Safety Evaluation of POMALYST (Pomalidomide) Treatment of Multiple Myeloma in Korea


Brief description of study

PMS period: 09Jun2017 ~ 08Jun2023 Target no.: 600patients

indication: POMALYST in combination with dexamethasone is indicated in the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib

The primary objective of this Drug Use Examination (DUE) is to evaluate safety of POMALYST (Pomalidomide) treatment of multiple myeloma in the clinical routine practice in Korea.

The secondary objective of this DUE is to evaluate effectiveness of POMALYST (Pomalidomide) treatment of multiple myeloma in the clinical routine practice in Korea.

Clinical Study Identifier: NCT03288974

Find a site near you

Start Over